menu search

MED / Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Medifast has seen a significant decline in its stock price and market cap in the past 2 years, reflecting investors' pessimism towards the company. The stock's underperformance may be attributed to inflationary pressures and concerns over new weight loss drugs from pharmaceutical giants Novo Nordisk and Eli Lilly. Concerns over weight loss drugs are overblown and the drugs could in fact be complementary to MED's offering. Read More
Posted: Aug 4 2023, 00:24
Author Name: Seeking Alpha
Views: 092036

MED News  

Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?

By Zacks Investment Research
November 2, 2023

Medifast (MED) Queues for Q3 Earnings: What Awaits the Stock?

Medifast's (MED) third-quarter results are likely to reflect concerns surrounding customer acquisition amid a challenging landscape. However, a focus more_horizontal

Medifast (MED) Gains on OPTAVIA Lifestyle Solution Strength

By Zacks Investment Research
September 11, 2023

Medifast (MED) Gains on OPTAVIA Lifestyle Solution Strength

Medifast's (MED) OPTAVIA program is a robust and adaptable solution focused on health and wellness. This holistic approach positions it for sustained more_horizontal

Why Is Medifast (MED) Down 7.4% Since Last Earnings Report?

By Zacks Investment Research
September 6, 2023

Why Is Medifast (MED) Down 7.4% Since Last Earnings Report?

Medifast (MED) reported earnings 30 days ago. What's next for the stock? more_horizontal

Medifast's (MED) Q2 Earnings Top Estimates, Sales Decline Y/Y

By Zacks Investment Research
August 8, 2023

Medifast's (MED) Q2 Earnings Top Estimates, Sales Decline Y/Y

Medifast's (MED) second-quarter 2023 results reflect lower sales and earnings on reduced Coach productivity and cost inflation. more_horizontal

Medifast (MED) Q2 Earnings and Revenues Surpass Estimates

By Zacks Investment Research
August 7, 2023

Medifast (MED) Q2 Earnings and Revenues Surpass Estimates

Medifast (MED) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings more_horizontal

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

By Seeking Alpha
August 4, 2023

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Medifast has seen a significant decline in its stock price and market cap in the past 2 years, reflecting investors' pessimism towards the company. Th more_horizontal

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

By Seeking Alpha
July 21, 2023

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Medifast, a health and wellness company, has seen its stock price decline by 76% since 2021, despite its Optavia platform helping over 2 million custo more_horizontal

Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help

By Seeking Alpha
June 14, 2023

Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help

I view Medifast's traditional business model at increasing risk from the growing popularity of GLP-1-based drugs. Recent M&A activity within the indus more_horizontal


Search within

Pages Search Results: